Pediatric tumor
Conditions
Interventions
HEM-SURVIVE structured follow-up model group:None
Conventional follow-up model group:None
Sponsors
Children's Hospital,Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
1 Years to 21 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with pediatric malignant hematologic tumors (acute lymphoblastic leukemia ALL, acute myeloid leukemia AML, lymphoma, etc.); 2. Completed primary tumor treatment (end of maintenance therapy or post-transplant) >= 12 months; 3. Currently no active tumor, in complete remission (CR) or stable condition; 4. Age 1–21 years (under 18 at initial diagnosis); 5. Able to complete follow-up and data collection, with informed consent signed by patient or guardian.
Exclusion criteria
Exclusion criteria: 1. Currently undergoing active treatment for tumor recurrence, progression, or secondary malignant tumors; 2. Complicated by severe organ dysfunction, severe psychiatric disorders, cognitive impairment, or neurological diseases, making follow-up evaluation impossible; 3. Complicated by other major genetic or systemic diseases that may significantly affect growth and development/organ function; 4. Severe non-tumor diseases with an expected survival of less than 1 year; 5. Poor expected follow-up compliance or refusal to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of a composite endpoint of severe late effects (Grade 3 or higher); | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance rate of the structured follow-up model;Change in Quality of Life (QoL) scale scores; | — |
Countries
China
Contacts
Public ContactZhang Jingying
Children's Hospital,Zhejiang University School of Medicine
Outcome results
None listed